Dynavax Technologies Co. (NASDAQ:DVAX) Shares Acquired by Northern Trust Corp

Northern Trust Corp lifted its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 10.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,457,848 shares of the biopharmaceutical company's stock after acquiring an additional 135,826 shares during the period. Northern Trust Corp owned 1.11% of Dynavax Technologies worth $18,617,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of DVAX. Russell Investments Group Ltd. grew its position in shares of Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares during the last quarter. Smartleaf Asset Management LLC grew its position in Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 2,034 shares during the last quarter. GAMMA Investing LLC grew its position in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock valued at $52,000 after buying an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in Dynavax Technologies in the 4th quarter valued at $71,000. Finally, Nisa Investment Advisors LLC grew its position in Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after buying an additional 1,076 shares during the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reiterated a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group lowered their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. StockNews.com lowered shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. Finally, JMP Securities decreased their target price on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Dynavax Technologies presently has an average rating of "Hold" and a consensus price target of $24.00.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX traded up $0.16 during trading on Monday, hitting $9.83. 1,518,886 shares of the company were exchanged, compared to its average volume of 2,219,384. The company has a market cap of $1.18 billion, a price-to-earnings ratio of 54.61 and a beta of 1.26. Dynavax Technologies Co. has a 1 year low of $9.22 and a 1 year high of $14.63. The firm's fifty day moving average price is $11.71 and its 200 day moving average price is $12.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). The company had revenue of $68.16 million for the quarter, compared to analysts' expectations of $70.01 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, sell-side analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.